Cipla: Straight-Up Q1 Beat with Strong Albuterol Play and India Growth

Cipla

(+3%) led the Nifty risers new on its Q1 FY26 numbers—outperformed estimates and showed strong execution across markets, thanks to stellar demand for respiratory therapies like Albuterol and resilient growth in India. Q1 FY26 in Brief Net Profit: ₹1,298 crore, up 10% YoY, beating consensus (~₹1,208 cr) Revenue: ₹6,957 cr (+4% YoY), slightly below Street (~₹7,106 cr) EBITDA: ₹1,778 cr (+4% YoY), margin of 25.6% vs est. 24.1% Segment Performance: Where the Growth Came From North America: $226 million in revenue—beat expectations (~$218 m). Albuterol ranked #1 in the U.S. Albuterol MDI market with ~19.5% share India (One India franchise): Grew 6% YoY, crossing ₹3,000 cr in Q1—highest-ever for opening quarter. Growth came via chronic therapy brands, trade generics, and consumer health products like Nicotex and Cipladine Africa/EMEU: Africa grew ~11% YoY (in USD); EMEU delivered ~8% growth, crossing market benchmarks comfortably Margin & Cost Drivers Gross margin expanded ~156 bps YoY to 68.8%, aided by a favorable product mix and chronic therapy dominance (61.5% share of billing) Employee and R&D costs rose, but lower raw material costs and mix shift helped keep margins steady above the company’s FY26 guidance Why the Market Loved It Exceeded profit and margin expectations while holding guidance—rare for pharma in a muted Q1 Delivered across geographies—India, North America, Africa, Europe—with momentum in chronic branded business and trade generics Analyst Takeaways & Forward View While US generics are under pricing pressure, Cipla is set to launch complex generics and peptides including Lanreotide, Nilotinib, and gSymbicort over FY26–FY27 Trade generics in India is bouncing back post-alliance/network transition—new launches and expanded distribution are key growth levers